The purpose of this notice of funding opportunity (NOFO) is to stimulate the development of new treatments for genital herpes that suppress shedding and lesion formation and reduce transmission.
This NOFO invites applications that propose research into a broad range of therapeutic approaches,
including but not limited to development of new or improved antivirals, monoclonal antibodies, therapeutic vaccines, and gene editing technologies for treatment of patients living with genital herpes.
This NOFO will use a milestone-driven, biphasic award mechanism.
Transition to the second phase is not guaranteed and will depend on the successful completion of milestones.